Novacyt Acquires Yourgene Health plc

WuXi AppTec Completes Acquisition of OXGENE

March 2, 2021

Biotechnology

WuXi AppTec, via its cell and gene therapy unit WuXi Advanced Therapies (WuXi ATU), completed the acquisition of Oxford-based OXGENE on March 2, 2021. The purchase brings OXGENE's gene-therapy discovery and viral-vector manufacturing technologies into WuXi ATU, expanding its capabilities and establishing its first European facility to better serve global cell and gene therapy customers.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Genezen Acquires uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

July 1, 2024

Biotechnology

Genezen has acquired uniQure's commercial gene therapy manufacturing operations and licensed viral-vector facility in Lexington, Massachusetts. The deal (funded in part by growth equity from Ampersand Capital Partners) transfers a commercially licensed AAV-capable manufacturing site and team to Genezen and includes strategic supply agreements to support uniQure's clinical portfolio and CSL Behring's commercial HEMGENIX product.

Invitae Acquires YouScript and Genelex

March 10, 2020

Healthcare Services

Invitae Corporation has agreed to acquire YouScript, a clinical decision support and analytics platform, for approximately $79.3 million (cash and stock) and Genelex, a pharmacogenetic testing laboratory, for approximately $20.7 million in Invitae common stock plus potential milestone shares. The acquisitions integrate Genelex's pharmacogenetic testing and YouScript's real-time prescribing decision support into Invitae's genetics offerings to accelerate use of pharmacogenetics at the point of care.

Veracyte Acquires Decipher Biosciences

February 3, 2021

Biotechnology

Veracyte, Inc. has entered into a definitive agreement to acquire Decipher Biosciences, a commercial-stage precision oncology company focused on urologic cancers, for $600 million in total consideration ($250 million cash and up to $350 million in stock). The acquisition expands Veracyte’s genomic cancer diagnostics menu, adds Decipher’s commercial tests and data assets, and is expected to accelerate revenue growth and global market reach.